We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. November 20 marks World COPD Day 2024, a worldwide ...
AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...
Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...
Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...
AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...
Mount Sinai analysis looks at the effectiveness of electrocardiograms analyzed via deep learning as a tool for early COPD detection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results